Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Cirrhosis
Interventions: blood draw and muscle biopsy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Incomplete Spinal Cord Injury, Muscular Dystrophy, Spina Bifida, Cerebral Palsy
Interventions: EA-KAFO; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 5 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Insomnia, Nightmares, Posttraumatic Stress Disorder
Interventions: Cognitive-Behavioral Insomnia and Nightmare Group; Behavioral
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy, Endocrine System Diseases, Orbital Diseases, Proptosis, Eye Diseases
Interventions: LASN01, Placebo; Drug
Lead sponsor: Lassen Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Beverly Hills, California • Palo Alto, California • San Diego, California + 6 more

Conditions: Paracentesis
Interventions: HoloUS app for ultrasound visualization; Device
Lead sponsor: Children's National Research Institute; Other
Eligibility: 18 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy Participants, Dyslipidemia
Interventions: AZD4954, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more

Conditions: Obesity, Overweight
Interventions: Confident Moves (CM) Intervention; Behavioral
Lead sponsor: Iowa State University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Traumatic Brain Injury (TBI) Patients, Severe Traumatic Brain Injury
Interventions: SeeMe Multimodal Auditory Command Protocol; Diagnostic Test
Lead sponsor: Stony Brook University; Other
Eligibility: 22 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Healthy Elderly Volunteers
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years to 80 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Knee Osteoarthritis
Interventions: Amniotic Suspension Allograft, Placebo; Biological · Drug
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 38
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 30 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more

Conditions: Human Papillomavirus Infections
Interventions: Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: NDO Full-thickness Plicator, Sham Control; Device
Lead sponsor: NDO Surgical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Orange, California • San Ramon, California • Denver, Colorado + 8 more

Conditions: Surgery
Interventions: Chlorhexidine Gluconate, Vehicle, DynaHex-2; Drug · Other
Lead sponsor: Medline Industries; Industry
Eligibility: 16 Years and older
Enrollment: 879 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Butte, Montana

Conditions: Healthy Volunteers, Sickle Cell Disease
Interventions: FT-4202/Placebo; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Long Beach, California • Oakland, California + 12 more

Conditions: Peanut Allergy
Interventions: ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal, Placebo Intramuscular; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more

Conditions: Kidney Transplant
Interventions: Exercise Rehabilitation; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions: Ixo-vec, Aflibercept; Genetic · Drug
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 75
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more

Conditions: Asthma
Interventions: Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 56
States / cities: Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more

Conditions: Enteral Nutrition
Interventions: TubeClear® intervention; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pre-Bronchiolitis Obliterans Syndrome
Interventions: ARINA-1, Standard of care only; Drug · Other
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Conditions: Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
Interventions: Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide; Behavioral · Drug
Lead sponsor: Noom Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Healthy
Interventions: PF-06946860, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Anaheim, California

Search by objective public record fields.

Novel Tracer Methods to Evaluate Muscle Protein Metabolism in Cirrhosis

Evaluating a New Knee-Ankle-Foot Brace to Improve Gait in Children With Movement Disorders

Initial Study of Insomnia/Nightmare Group Treatment for Posttraumatic Stress Disorder (PTSD)

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Augmented Reality Ultrasound Guidance

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Confident Moves Intervention Efficacy Trial: Obesity Care Settings

SeeMe: Using Automated Facial Tracking to Detect Voluntary Behavior in Brain Injury

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

A Study to Determine the Effectiveness of Endoscopic Full-Thickness Plication for the Treatment of GERD

Preoperative CHG Cloth on Healthy Subjects

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

TubeClear® Evaluation in Pediatric Patients (Phase I)

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants